College of Health Science and Technology

undefined

Xu Zizhen

Associate Professor

Email: xuzizhen@126.com

Tel: 64370045-610506

Research direction: clinical and experimental hematology

Bio

Doctor of internal medicine (Hematology), School of medicine, Shanghai Jiaotong University; Associate Professor, School of medical technology, School of medicine, Shanghai Jiaotong University; master's supervisor; deputy director of experimental diagnosis teaching and Research Office, School of medical technology, School of medicine, Shanghai Jiaotong University. Visiting scholar of Laennec medical school, Lyon, France, and adjunct professor of medical education innovation department, University of Ottawa medical school, Canada.  Presided over the projects of the National Natural Science Foundation of China, the scientific research project of the Shanghai Municipal Health and Family Planning Commission, the Shanghai charity Cancer Research Fund, participated in 6 projects of the National Natural Science Foundation of China and the Shanghai Natural Science Foundation, and published more than 10 SCI papers of the first author / corresponding author. Selected into the high altitude discipline construction plan of Shanghai Municipal Education Commission, the overseas study visit plan for young college teachers of Shanghai Municipal Education Commission, and the Guangci visiting scholar plan of Ruijin Hospital. It won the second prize of the national outstanding achievements in scientific research (Science and Technology), the "excellent laboratory physician" of the Shanghai Medical Association, the special prize of the excellent online teaching course cases of the medical laboratory specialty of the national medical colleges, the second prize of the middle-aged and young teachers' lecture competition of the medical laboratory technology of the national medical colleges, and the second prize of the micro class competition of the medical laboratory specialty of the national medical colleges.

Publications

  • Xu Z, Dargaud Y, Chamouard V, Le Quellec S, Lienhart A, Meunier S, Rugeri L.A single-centre study of management of pregnant women with von Willebrand disease.Haemophilia. Haemophilia. 2019 Jan;25(1):e54-e57.

  • Jin Z, Xiang R, Qing K, Li X, Zhang Y, Wang L, Zhu H, Mao Y, Xu Z, Li J.The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.Ann Hematol. 2018 May 15.

  • Xu ZZ, Shen JK, Zhao SQ, Li JM.Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.Leuk Lymphoma. 2018 Jun;59(6):1451-1460.

  • Z. Xu, L. Rugeri, A. Lienhart, Y. Dargaud, C. Management of pregnant women with von Willebrand disease:a french single-center experience. 10th Annual Congress of the European Association for Haemophilia and Allied Disorders.N°: EAHAD17-LB-1312

  • Qing K, Jin Z, Fu W, Wang W, Liu Z, Li X, Xu Z*, Li J.Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma.J Hematol Oncol. 2016 Aug 23;9(1):72.

  • Jin Z, Qing K, Ouyang Y, Liu Z, Wang W, Li X, Xu Z*, Li J.Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.J Exp Clin Cancer Res. 2016 Mar 24;35(1):52.

  • Xu ZZ, Fu WB, Jin Z, Guo P, Wang WF, Li JM.Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma.Leuk Lymphoma. 2016 Apr;57(4):888-98.

  • Xu ZZ, Zhao BB, Xiong H, Wei BW, Wang YF.Serum BAFF and APRIL levels in patients with autoimmune hemolytic anemia and their clinical significance.Int J Hematol. 2015 Oct;102(4):394-400.(IF 1.846)

  • Zhao YB, Li JM, Wei BW, Xu ZZ*.BAFF level increased in patients with autoimmune hemolytic anemia.Int J Clin Exp Med. 2015 Mar 15;8(3):3876-82.

  • Xu ZZ, Wang WF, Fu WB, Wang AH, Liu ZY, Chen LY, Guo P, Li JM.Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.Leuk Lymphoma. 2014 May;55(5):1151-7.

  • Xu ZZ, Xia ZG, Wang AH, et al. Activation of the PI3K/AKT/mTOR pathway in diffuse large B-cell lymphoma: Clinical significance and inhibitory effect of rituximab. Ann Hematol. 2013 Oct;92(10):1351-8.